Stock Ratings / Health Care / MLTX / options

JANX (33) LTGO (55) CTY (61) HROW (71) ⌘ Pro Terminal →

MoonLake Immunotherapeutics (Class A) (MLTX) Options Positioning, Max Pain & Unusual Sweeps

$12.57 +2.11% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

MoonLake Immunotherapeutics (Class A) (MLTX) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $1.07B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MLTX)Realized 20D OHLCV Swing Band: ±12.5%

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (MLTX)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for MLTX.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MLTX)

✓Walkthrough of MLTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MLTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -23.26%⚡ TESTING RESISTANCE

2026-10-30O $12.44H $12.63L $11.71C $12.57VOL 1.13M

RES: $12.68SUP: $8.61SMA50: $12.52SMA200: $16.46

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MLTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MLTX Butterfly Map → + Track MLTX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MLTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MLTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MLTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MLTX)

Health Care Rank #445 of 1016 ⚔️ JANX vs MLTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MLTX vs. JANX, LTGO, CTY, HROW)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, MoonLake Immunotherapeutics (Class A) (MLTX) ranks #445 by composite RQD confidence (46/100, grade D) and #356 by equity capitalization ($1.07B). Within this direct 5-issuer industry benchmark cohort, MLTX leads on earnings valuation at N/A trailing P/E, while HROW leads on capital efficiency and profitability with 42.9% ROIC and 75.1% gross margin. HROW currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with MLTX at 46/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MLTX ACTIVE MoonLake Immunotherapeutics (Class A)	D	46/100	—	—	-35.0%	+2.11%	$1.07B	Benchmark Subject
JANX Janux Therapeutics Inc.	E	33/100	—	—	-13.8%	-1.22%	$1.09B	/janx-vs-mltx →
LTGO Latigo Biotherapeutics Inc.	D+	55/100	—	—	—	-1.83%	$1.03B	/ltgo-vs-mltx →
CTY City Therapeutics Inc.	C-	61/100	—	—	—	+2.26%	$1.11B	/cty-vs-mltx →
HROW Harrow Inc.	B-	71/100	—	75.1%	42.9%	+2.04%	$1.12B	/hrow-vs-mltx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001821586

In its most recent audited fiscal period (FY2025, filed 2025-12-31), MoonLake Immunotherapeutics (Class A) (MLTX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$227.3M, operating cash flow of -$196.0M, and free cash flow of -$196.0M (-67.4% YoY). On the balance sheet, MLTX closed FY2025 with $424.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$227.3M	-$196.0M	-$196.0M	$424.4M	—
FY2024 (FY)	2024-12-31	$0	-$118.9M	-$116.6M	-$117.1M	$477.9M	—
FY2023 (FY)	2023-12-31	$0	-$36.0M	-$42.8M	-$42.8M	—	—

3. MLTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MLTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, MoonLake Immunotherapeutics (Class A) (NASDAQ: MLTX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $12.57 (+2.11% 1D, market cap $1.07B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MLTX ranks #445 in composite RQD confidence.

How does MLTX compare to JANX and LTGO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MLTX carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, JANX (Janux Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -13.8%, cap $1.09B) and LTGO (Latigo Biotherapeutics Inc.) posts a D+ grade (55/100 RQD, P/E N/A, ROIC —, cap $1.03B). Among the 5-stock peer group, MLTX leads on earnings multiple (N/A) while HROW leads on capital efficiency (42.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MLTX?

Per MLTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001821586), MoonLake Immunotherapeutics (Class A) generated $0 in revenue, -$227.3M in net income, and -$196.0M in free cash flow against $424.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MLTX trading relative to its 50-day, 200-day, and 52-week technical levels?

MLTX last traded at $12.57 (+2.11% on volume of 4,097,306 shares), positioning the stock +0.40% above its 50-day simple moving average ($12.52) and -23.63% below its 200-day simple moving average ($16.46). Across its 52-week range of $9.46 to $23.29, MLTX sits at the 22.5% percentile with a 14-day RSI of 50.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($11.00 to $14.14).

MLTX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is MLTX's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for MLTX.

Direct Sub-Reports: MLTX RQD Cockpit MLTX 12M Forecast MLTX Earnings & Move MLTX Dividends & DRIP MLTX Insiders & 13F MLTX Whale Options MLTX Profit Sankey MLTX News & Why